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Bacteroides thetaiotaomicron Ameliorates Colon Inflammation 
in Preclinical Models of Crohn’s Disease
Margaret Delday,*,† Imke Mulder , PhD,*,  Elizabeth T. Logan,*,† and George Grant, PhD*,†
Background: Alterations in the gut microbiota are strongly associated with the development of inflammatory bowel disease (IBD), particularly 
with Crohn’s disease, which is characterized by reduced abundance of commensal anaerobic bacteria including members of the Bacteroides genus. 
Our aim was to investigate the protective effects of Bacteroides thetaiotaomicron, an abundant member of this genus, in different rodent models 
of IBD.
Methods: We assessed the effect of B. thetaiotaomicron administration on primary readouts of colitis (weight loss, histopathology, and immune 
parameters) in dextran sodium sulphate (DSS) and interleukin-10 knockout (IL10KO) models of IBD. Efficacy of a freeze-dried bacterial formu-
lation and a purified recombinant protein of B. thetaiotaomicron was also investigated.
Results: B. thetaiotaomicron showed protective effects in both DSS and IL10KO rodent models, as demonstrated by significant amelioration 
of weight loss, colon shortening, histopathological damage and immune activation. This efficacy was not exclusive to actively growing bacte-
rial preparations but was retained by freeze-dried cells of B. thetaiotaomicron. A pirin-like protein (PLP) of B. thetaiotaomicron, identified by 
microarray analysis during coculture of the bacterial strain with Caco-2 cells, reduced pro-inflammatory NF-κB signalling in these intestinal 
epithelial cells. Recombinant PLP partially recapitulated the effect of the whole strain in a rat DSS model.
Conclusions: B. thetaiotaomicron displays strong efficacy in preclinical models of IBD and protects against weight loss, histopathological changes 
in the colon and inflammatory markers. These data indicate that the live strain or its products may be a novel alternative to current treatment 
options for Crohn’s disease.
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INTRODUCTION
Crohn’s disease (CD) is a chronic, relapsing-remitting, 
autoimmune inflammatory bowel disease (IBD) that can affect 
any part of the gastrointestinal tract, unlike the other com-
mon form of IBD, ulcerative colitis (UC), which mostly affects 
the colon. Crohn’s disease is characterized by discontinuously 
affected areas of transmural granulomatous inflammation and/
or fistula.1 Its clinical presentations include bloody diarrhea, 
abdominal cramps and pain, with patients often requiring 
long-term medical therapy, periodic hospitalization and even 
surgical intervention.2 Linear growth deficiency and delayed 
puberty are detected in up to 85% of patients diagnosed with 
CD in childhood.3 In addition, extra-intestinal complications 
may develop in systemic organs such as the joints, skin and 
eyes.4, 5 Adult-onset IBD, which presently accounts for 60%–
65% of all cases, first presents between 18 to 40 years of age, 
while elderly-onset IBD (10%–15% of cases) appears around 
50 to 70  years of age.6–9 Pediatric-onset IBD first occurs in 
childhood, and approximately 20%–30% of all CD cases are 
diagnosed before the age of 20.7, 9
Aminosalicylates and corticosteroids are often the first-
line therapy for mild to moderate IBD, whereas biologics such 
as tumor necrosis factor (TNF)-alpha inhibitors (eg, inflix-
imab, adalimumab and golimumab) are generally reserved for 
patients with fistulising CD or disease that is nonresponsive 
to other therapies. However, there has been an exponential 
increase in the number of patients exposed to higher doses of 
anti-TNFs earlier in their disease course.10 There are safety con-
cerns regarding the long-term use of potent immunosuppres-
sive agents due to the development of severe side effects,2, 11–13  
and this presents an ongoing, unmet clinical need for alterna-
tive treatment options.
The exact causes of IBD are still unknown, but the dis-
ease is thought to develop as the result of abnormal intestinal 
immunity and altered gut microbiota related to environmental 
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factors such as diet and infection in genetically susceptible 
individuals. While the gut microbiota is now considered an 
essential factor in the IBD inflammatory cascade, it is yet to 
be resolved whether it is an initiating trigger or secondary to 
the development of IBD. Crohn’s disease is characterized by 
decreased microbiota diversity in the gut, an altered and unsta-
ble microbiota composition, increased numbers of bacteria 
attaching to the intestinal epithelium and altered relative abun-
dances of health-associated taxa and pathobionts.14–17 In par-
ticular, reduced relative abundance of commensal anaerobic 
bacterial species of the genera Bacteroides, Faecalibacterium, 
Eubacterium and Lactobacillus and increased abundance of 
pathobionts, including Fusobacterium and Escherichia, has 
been observed16–18
Bacteroides thetaiotaomicron is a prevalent species within 
the Bacteroides genus of the human gut microbiota. It has pre-
viously been shown that B.  thetaiotaomicron has anti-inflam-
matory properties, can increase mucosal barrier function and 
can limit pathogen invasion.19–21 On the basis of this informa-
tion, coupled with data from our in-house in vitro screening 
platform, we decided to assess the activity of B. thetaiotaomi-
cron type strain DSM 2079 (BT) in well-characterized rodent 
models of colitis. We here demonstrate that BT is efficacious 
in reducing the primary disease readouts in dextran sulphate 
sodium (DSS) mouse and rat models of colitis and in interleu-
kin-10 knockout (IL10KO) mice. Treatment with BT could, 
thus, potentially reverse inflammatory responses and ultimately 
reduce symptoms of CD.
MATERIALS AND METHODS
B. thetaiotaomicron and Pirin-Like Protein (PLP) 
Treatment
Bacteroides thetaiotaomicron type strain DSM 2079 (BT) 
was cultured in anaerobic Wilkin’s Chalgren Medium (Oxoid, 
UK) overnight at 37°C before dosing. Freeze-dried BT was 
fermenter-grown, freeze-dried, milled and sieved; mice were 
subsequently dosed with 250  mg of freeze-dried BT per day. 
Pirin-like protein BT_0187 (PLP; 861-YHH-02P; 29.2  kDa) 
was produced at GTP Technology (Labege, France) and encap-
sulated in size 9 capsules at Encap (Edinburgh, UK), with each 
capsule containing 4 nmol PLP.
Colitis Models
Specific-pathogen free (SPF) female C57BL/6 mice (6 
weeks old) were obtained from Harlan (UK) and housed in 
pairs in flexifilm isolators. After an acclimatization period 
of 7–10  days, the mice were dosed orally daily with a viable 
overnight culture (1  ×  1010 CFU/kg BW) of BT for 14  days. 
Control animals were dosed with culture medium alone. From 
day 8 onward, the mice were given 3% dextran sodium sul-
phate (DSS, 36-50kDa, MP Biomedicals UK) in their drinking 
water for 6 days until the end of the study. Untreated controls 
remained on culture medium and had free access to sterile 
water. Experiments were performed as 2 independent cohorts.
SPF male Hooded Lister (9–10 weeks old) rats were 
dosed orally daily with BT (3 × 1010 CFU/kg BW) for 14 days, 
and 16 controls were given culture medium alone. On days 
8–14, the BT-treated rats and 8 controls were given DSS in ster-
ile water for 7 days (4% DSS for 5 days and 2% DSS for 2 days). 
Nontreated controls had free access to sterile water.
SPF male Hooded Lister rats were dosed orally with PLP 
capsules (12 nmol/rat/d) or placebo for 7 days. Rats were also 
given DSS in sterile distilled water (4% DSS for 5 days and 2% 
DSS for 2 days) during this time. Nontreated control rats had 
free access to sterile water.
SPF C57BL/6 homozygous IL10KO mice were purchased 
from the Jackson Laboratory (Bar Harbor, ME,  USA). They 
were housed and bred over 3 generations within flexifilm isola-
tors. Weanling mice (20 days old) were orally dosed for 13 weeks 
(2–3 times a week) with a viable culture (1 × 1010 CFU/kg BW) 
of BT. Experiments were performed as 2 independent cohorts.
Animals on all studies were checked twice daily for gen-
eral health condition and in particular for blood in the feces. 
Water consumption, food intake and body weight were moni-
tored daily. Animal sacrifice, tissue sampling and processing of 
all studies were carried out using similar procedures. At termi-
nation, ascending colon tissues were collected and fixed in neu-
tral buffered formalin (NBF; Sigma-Aldrich,  St. Louis, MO, 
USA) for histology or stored in RNAlater (Qiagen, Manchester, 
Lancs, UK) for molecular analysis.
The University of Aberdeen is licensed under the UK 
Animals (Scientific Procedures) Act 1986. The local Animal 
Welfare and Ethical Review Board (AWERB), the animal 
welfare unit, and the appropriate governmental inspectorate 
monitor and review all animal studies. The management and 
experimental procedures used were approved by AWERB and 
conducted under the auspices of PPL 60/4360 and 60/3690.
Histopathology Analysis of Ascending Colons
 Immediately post dissection, colon length was measured. 
Ascending colon samples were dissected at the exact same gut 
location between experiments and further divided into 3 pieces 
for the different analyses carried out. This was paramount for 
intestinal sampling due to the heterogeneity along its length.22 
Samples for histology were fixed in 10% NBF and processed 
to 8100-resin (TAAB Laboratories, Aldermaston, Berks, UK) 
according to manufacturer’s instructions. Multiple ascend-
ing colon pieces were orientated for transverse sectioning per 
tissue/block. Four-micron sections were cut (Reichert Jung 
microtome) and stained with hematoxylin and eosin (H&E) 
(Sigma-Aldrich). Two slides were prepared for each sam-
ple, and sections were taken at least 400 µm apart to increase 
the area of tissue examined. An Axioskop 50 upright micro-
scope (Zeiss, Cambridge, Cambs, UK) equipped with x20/0.50 
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Plan Neofluar objective and Qimaging QICAM Fast cooled 
12-bit camera controlled by Image Pro Plus software (Media 
Cybernetics, Wokingham, UK) was used to image the com-
plete transverse cross section of at least 2 colon pieces. This 
resulted in a mean number of digitized images of 70 per ascend-
ing colon, which represented 2 complete transverse cross sec-
tions. The number of fields of view per tissue varied due to 
the thickening of the mucosa, seen particularly in the IL10KO 
groups. Only complete transverse sections of ascending colons 
were imaged and used for histopathological scoring. This was 
found to be particularly important in the DSS experiments as 
the highest grade of pathology was usually adjacent to the mes-
enteric attachment.
Two experienced, blinded individuals used a pathology 
scoring method based on Berg et al23 to allocate a single score 
per field of view. The scores ranged from 0 to 4, where 0 had no 
pathology, the fields of view displayed shallow crypts with no 
or few infiltrating inflammatory cells, an intact epithelium was 
observed and goblet cells appeared full of mucin. Fields scor-
ing 1 displayed some epithelial hyperplasia resulting in a slight 
increase in the depth of the crypts, and there was slight deple-
tion of mucin from the goblet cells, but the epithelium remains 
intact. Fields scoring a 2 had crypts which seemed deeper 
with distinct evidence of epithelial hyperplasia and depletion 
of mucin from goblet cells, but infiltrating inflammatory cells 
were evident and could be multifocal in nature, though the 
infiltrates were not seen in the submucosa. Grade 3 fields of 
view displayed lesions involving a larger area of the mucosa or 
were more frequent than that seen in grade 2. The lesions did 
not involve the submucosa. The luminal epithelial cells could 
exhibit small erosions. The lesions were not transmural. Grade 
4 pathology was characterized by the crypt epithelium seem-
ing to be eroded, luminal epithelial cells seeming irregular—
sometimes with complete loss. Transmural infiltrate was often 
associated with complete loss of epithelial cells into the lumen. 
Areas of almost complete mucin depletion could be seen. The 
mean percentage of fields of view at a given score was calcu-
lated, and a comparison was made between treatment groups.
Microarray Analysis
Caco-2 cells were seeded into 35-mm dishes in 10% 
FBS/4  mM L-glutamine/1  ×  antibiotic antimycotic/DMEM 
media (fetal bovine serum [FBS]), 200 mM L-glutamine, antibi-
otic antimycotic solution 100 × stabilized, Dulbecco’s Modified 
Eagle’s Medium—high glucose (DMEM) (all from Sigma-
Aldrich) and incubated at 5% CO2 at 37°C for 6  days. Cells 
were washed twice with Hank’s Balanced Salt Solution (HBSS) 
(Sigma-Aldrich) and then synchronized in serum and antibiotic 
free media (DTS) for 24 hours (DMEM , 200 mM L-glutamine, 
500 µl 20 µgml-1 sodium selenite, and 500 µl 500 µgml-1 apo-Trans-
ferrin, Sigma-Aldrich). Cells were treated with flagellin of 
Salmonella enteritidis (10 ng/well), phorbol-12-myristate-13-ac-
etate (PMA; 150  ng/well) or interleukin-1 (IL-1; 10  ng/well). 
Bacteroides thetaiotaomicron type strain DSM 2079 was added 
at 109 CFU/mL and incubated for 2 hours. Bacterial culture 
was then removed, and RNA was prepared using Nucleospin II 
RNA Extraction Kit and reverse transcribed to cDNA with the 
SuperScript II Reverse Transcriptase (ThermoFisher, Hemel 
Hemstead, Hertfordshire, England) following manufacturer’s 
instructions. Samples were processed using the One-Color 
DNA Labeling kit, Hybridization kit, Sample Tracking Control 
kit and Wash Buffer kit (Roche NimbleGen Inc., Madison, WI, 
USA) and hybridized to a Bacteroides thetaiotaomicron VPI-
5482-specific microarray (Roche NimbleGen Inc.) according to 
the manufacturer’s instructions. The files were then analyzed 
using NimbleScan software (Madison, WI, USA).
Mouse ascending colon tissues were lyzed in Trizol 
(Invitrogen,  Carlsbad, CA, USA). RNA was isolated using 
standard chloroform/isopropanol steps. Total RNA was further 
purified with the RNeasy Kit (Qiagen), including an RNase-free 
DNase I (Qiagen) digestion step. Total RNA was processed into 
biotin-labeled cRNA using the One-Cycle Target Labeling Kit 
(Affymetrix, Santa Clara, CA, USA) or biotin-labeled aRNA 
using the 3’ IVT Express Kit (Affymetrix). Hybridization to the 
GeneChip NuGO Mouse Array (Affymetrix) on a GeneChip 
Fluidics Station 450 (Affymetrix) was performed at the Institute 
of Medical Sciences Microarray Core Facility (University 
of Aberdeen, Aberdeen, UK). Chips were scanned with an 
Affymetrix GeneChip Scanner 3000. Image quality analysis was 
performed using the Gene Chip Operating Software (GCOS) 
(Affymetrix). Further data analysis was performed using R 
(www.rproject.org) and Bioconductor (www.bioconductor.
org). The moderated F test provided by the Bioconductor 
package limma was used to test for differential expression. 
Differences were considered significant with P < 0.05 using the 
Benjamini and Hochberg false discovery method. Microarray 
data were submitted to the National Center for Biotechnology 
Information (NCBI) Gene Expression Omnibus (accession 
number GSE118526; www.ncbi.nlm.nih.gov/geo).
Quantitative Reverse Transcriptase Polymerase 
Chain Reaction
mRNA was extracted from the ascending colon using 
TRIzol (Invitrogen) followed by the RNeasy kit and Oligotex 
mRNA mini kit (Qiagen) according to the manufacturer’s instruc-
tions; 2 μg of total eukaryotic RNA, isolated from the ascending 
colon, was reverse-transcribed into cDNA using the High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems) with 
random primers. This was followed by quantitative polymerase 
chain reaction (qPCR) using a 7500 Fast Real-Time PCR System 
(Applied Biosystems), with the QuantiFast SYBR Green PCR 
Kit (Qiagen) and QuantiTect Primer Assays (Qiagen), for hypox-
anthine-guanine phosphoribosyltransferase (Hprt), interleukin-6 
(Il6), interleukin-1β (Il1b), tumor necrosis factor α (Tnfα), C-X-C 
motif chemokine 10 (Cxcl10), chemokine (C-C motif) ligand 3 
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(Ccl3) and regenerating islet-derived protein 3-gamma (Reg3g). 
Polymerase chain reaction cycling conditions were as follows: 1 
cycle at 95°C for 5 minutes, followed by 40 cycles at 95°C for 10 
seconds and at 60°C for 30 seconds, ending with a dissociation 
step. All samples were run in triplicate. Hypoxanthine-guanine 
phosphoribosyltransferase was used for normalization purposes. 
All data were analysed on a logarithmic scale with base 2 by one-
way ANOVA with a significance cutoff of P < 0.05. Differences 
were back-transformed to calculate fold changes.
Luciferase Assay
Caco-2 cells were transfected by adding DMEM plus 4 mM 
of L-glutamine media, including appropriate quantities of PLP in 
expression vector, pLuc-GL3\NF-κB, Renilla luciferase construct, 
and Fugene 6 transfection reagent (Promega, Southampton, 
Hants, UK) to appropriate wells; cells were then incubated for 
48 hours at 5% CO2 at 37°C. Cells were synchronised 24 hours 
before stimulation in serum-free media. Subsequently, cells were 
treated with flagellin of Salmonella enteritidis (10 ng/well), phor-
bol-12-myristate-13-acetate (PMA; 150 ng/well) or interleukin-1 
(IL-1; 10 ng/well) for 9 hours (5% CO2 at 37°C). The media was 
removed and the 24 well plates containing the cells were frozen 
at −80°C. The plates were warmed to room temperature for 30 
minutes, 150 µl of Dulbecco’s Phosphate Buffered Saline (PBS; 
Sigma-Aldrich) was added to each well and cells were scraped 
off and 100 µl transferred to a 1.5-mL microfuge tube. Luciferase 
activities in the 100 µl samples were determined using the Dual-
Glo luciferase assay system (Promega, UK) on an Envision 2102 
Plate Reader.
Statistical Analysis
Analysis of data was conducted using GraphPad Prism 
7.  One-way ANOVA was applied to datasets comparing more 
than 2 treatment conditions at a single timepoint followed by the 
Tukey multiple comparison test. Two-way ANOVA was applied 
to datasets comparing 2 or more treatment conditions where data 
was also collected over multiple timepoints. Two-way ANOVA was 
followed by the Sidak multiple comparison test when comparing a 
single condition to another condition or the Tukey multiple com-
parison test when comparing multiple conditions to multiple other 
conditions. Unpaired Student t test was used to analyse means 
from 2 conditions only at a single timepoint. All data were plot-
ted as mean ± standard deviation, except quantitative PCR, which 
was plotted as mean ± standard error of the mean.
RESULTS
B. thetaiotaomicron Is Protective in  
Chemically-Induced Acute DSS-Colitis in Mice
Dextran sodium sulphate (DSS)  causes acute colitis 
with similarities to IBD in C57Bl/6 mice.24 This well-estab-
lished preclinical model was used to test if  administration of 
B.  thetaiotaomicron (BT) could prevent or limit this severe, 
chemically induced colitis in mice. C57Bl/6 mice were dosed 
daily with BT for 8 days, while control mice were dosed with 
culture medium. The BT-dosed mice and control mice were 
then treated with 3% DSS for 6 days. Untreated control mice 
were dosed with culture medium without DSS treatment.
Mice given DSS alone displayed notable weight loss 
(P < 0.001 versus control), mainly over days 4–6 of DSS expo-
sure (Fig. 1A). This weight loss was significantly reduced in mice 
dosed with BT (P < 0.01 versus DSS at day 4 and P < 0.0001 
at day 5 and 6; Fig. 1B). Food and water intake was measured 
daily, and mean total intakes were not significantly differ-
ent between groups (data not shown). A  grading assessment 
scheme based on Berg et al23 (Fig. S1) was used to assess colon 
histopathology with grades ranging from 0 (no pathology) to 
4 (highest pathology). DSS-induced histopathological damage 
was generally moderate-severe, with 27.1% of the fields of view 
showing high scores (grades 2–4) and only 27.6% fields of view 
with no pathology (Fig. 1C). All pathology grades were signifi-
cantly different when comparing the control group with the 
DSS-treated group (grade 0, P < 0.0001; grade 1, P = 0.0218; 
grade 2, P = 0.0013; grade 3, P = 0.0229; grade 4, P = 0.0010). 
Most mice dosed with BT had only mild-moderate disruption 
of the colon. The majority of fields of view had no (grade 
0) or low (grade 1) pathology, with only 9.3% of the fields of 
view having higher pathology (grades 2–4). Histopathological 
scores were significantly reduced (grade 0, P = 0.0031; grade 
4, P = 0.0006) in DSS-treated mice dosed with BT compared 
with DSS alone. In the control group, 92.2% of fields of view 
had grade 0 (no pathology), with 7.8% at grade 1 (low-grade 
pathology). Cellular infiltration, mucin depletion and epithelial 
erosion were all less evident in mice dosed with BT (Fig. 1D). 
This was reflected in the significant downregulation of expres-
sion of inflammation-related genes such as Il6, IL1b, Tnfα and 
Cxcl10 compared with DSS alone (Fig. 1E).
B. thetaiotaomicron Is Protective in an IL-10KO 
Mouse Model of Colitis
Interleukin-10 knockout mice spontaneously develop 
intestinal inflammation and transmural pancolitis between 2 
and 4  months of age. Disease progression has many features 
of CD, so IL10KO mice are widely used as a model for this 
disease.24–26 The aims of this study were to establish if  BT could 
ameliorate the moderate spontaneous colitis that develops in 
the IL10KO mouse and to investigate the effects of bacterial 
dosing on gut integrity and immune parameters. Interleukin-10 
knockout mice were dosed with BT 3 times a week from wean-
ing at 3 weeks old, for a total period of 13–14 weeks. Control 
IL10KO mice were dosed with culture medium alone.
Bacteroides thetaiotaomicron treatment significantly 
improved weight gain, both over time (P < 0.05 at days 97–100 
interval; Fig. 2A) and assessed as total weight change at day 93 
D
ow
nloaded from
 https://academ
ic.oup.com
/ibdjournal/article-abstract/25/1/85/5095645 by U
niversity of Aberdeen user on 14 D
ecem
ber 2018
89
Bacteroides thetaiotaomicron Ameliorates Colon Inflammation in Preclinical Models of Crohn’s DiseaseInflamm Bowel Dis • Volume 25, Number 1, January 2019 
(P = 0.0050), which was the final time-point before staggered 
termination (Fig. 2B). Interleukin-10 knockout mice displayed 
moderate-severe pathology with 57.83% of the fields of view 
having the highest grades (3 and 4)  of pathology (Fig.  2C). 
BT-dosed IL10KO mice had a mild-moderate pathology in 
which most fields of view (68%) had low levels (grades 0 and 1) 
FIGURE 1. B. thetaiotaomicron is protective in C57Bl/6 mice with acute DSS-colitis. A and B, Weight change of DSS-treated mice dosed with  
B. thetaiotaomicron (BT) or culture media for 15 days. Mice given DSS alone displayed major weight loss, mainly over days 4–6 of DSS exposure, and 
this weight loss was significantly reduced in mice dosed with BT. C, Histopathology scores showed BT treatment of DSS-induced colitis significantly 
increased the percentage fields of view with 0 score (no pathology) and significantly decreased the percentage fields of view at score 4 (highest 
pathology). D, Representative images of H&E stained sections of ascending colons from indicated groups; L = lumen; GC = goblet cell; E = epithelium; I 
= infiltrate. E, The relative gene expression of the inflammatory mediators Il6, IL1b, Tnfα and Cxcl10 was significantly reduced with BT treatment.
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FIGURE 2. B. thetaiotaomicron is protective in an IL10KO mouse model of colitis. A, Body weight monitoring of IL10KO mice dosed 3 times weekly 
with BT or culture media for 13–14 weeks from weaning showed that BT treatment significantly improved weight gain, both over time and (B) 
assessed as total weight change at day 93. C, BT treatment of IL10KO mice resulted in an increase in the percentage fields of view with no  
pathology and a reduction in the fields of view scoring the highest grade of pathology. D, Macroscopic images (top panel) demonstrate the increase 
in ascending colon diameter from IL10KO mice compared with the WT and IL10KO/BT groups. Representative images of H&E stained ascending 
colon sections (middle panel) illustrate the degree of crypt hyperplasia and infiltrating inflammatory cells which occurred in these mice relative to 
the WT and IL10KO/BT; I = infiltrating cells; L = lumen. Representative images from WT, IL10KO, and IL10KO/BT (bottom panel) illustrate the types of 
images used for pathology scoring; L = lumen; E = epithelium; GC = goblet cells; C = crypt; I = infiltrate. E and F, Transcriptomics of ascending colon 
of BT-treated IL-10KO mice shows differential gene expression of 107 transcripts between IL10KO- and IL10KO/BT-treated mice. BT treatment partic-
ularly reduced the expression of genes related to the inflammatory response.
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of pathology. There was a significant difference at grade 4 
(P  =  0.0025), with grade 3 trending towards significance 
(P = 0.0761). Macroscopically, colons varied from being very 
swollen and distended—indicative of extensive inflamma-
tion, immune cell infiltration and disruption to the tissue—
through to the narrow form of wildtype controls. An overall 
visual assessment of the colons indicated that most IL10KO 
mice had severe pathological changes, whereas most BT-dosed 
IL10KO mice exhibited only moderate disruption (Fig.  2D). 
Microscopic examination illustrated the degree of crypt hyper-
plasia in IL10KO mice relative to IL10KO/BT and wildtype 
mice (Fig. 2D). The increased thickness of the mucosa was pri-
marily due to crypt hyperplasia, and this, along with an increase 
in infiltrating cells, was responsible for the overall increased 
colon diameter.
Comparative transcriptome analysis of ascending colon 
tissue of IL10KO and IL10KO/BT-treated mice showed dif-
ferential expression of a wide range of genes associated with 
inflammatory responses between the 2 treatment groups 
(Fig.  2E), with 107 gene expression levels significantly differ-
ent. Expression of pro-inflammatory genes (such as Arg1, Il6, 
Ccl3, Spp1 and Il1a) and genes involved in pathogen recogni-
tion (Clec4e, Irg1) was particularly lower in IL10KO/BT mice 
(Fig. 2F).
Lyophilized B. thetaiotaomicron Maintains Its 
Protective Activity in Murine DSS-Colitis
Next, the activity of BT in a freeze-dried formulation 
(BTFD) was assessed for its ability to ameliorate colitis as the 
preferred target formulation for clinical use. C57Bl/6 mice were 
dosed daily with BTFD for 8 days. Another group of mice were 
dosed with a growing culture of BT, and control mice were 
dosed daily with culture medium. All animals were then given 
3% DSS for 6  days. Untreated control mice were dosed with 
culture medium without DSS treatment. Administration of BT 
or BTFD limited weight loss caused by DSS in C57Bl/6 mice 
(Fig. 3A and B). There was a major decline in body weight in 
mice dosed with DSS, but the losses were significantly reduced 
when the mice were also dosed with liquid culture of BT 
(P < 0.001 versus DSS) or freeze-dried BT (P < 0.0001 versus 
DSS). Weight loss was significantly reduced by BT from day 4 
of DSS treatment onward, whereas BTFD showed significant 
effects from day 5 of DSS exposure onward. Colon lengths in 
mice treated with DSS were reduced compared with control 
mice (P < 0.001; Fig. 3C) but were less affected by DSS if  mice 
were also given BT (P < 0.001 versus DSS) or BTFD (P < 0.001 
versus DSS). DSS-induced colon inflammation was reduced in 
mice dosed with BT and BTFD (Fig.  3D and E). Ascending 
colon pathology in DSS-treated mice was generally moder-
ate-severe, with 34.8% of the fields of view showing high histo-
pathology scores (grades 2–4) and only 38% fields of view with 
no pathology (Fig. 3D and E). All grades of pathology showed 
significant differences when comparing the control with DSS-
treated mice (grade 0, P < 0.0001; grade 1, P = 0.0004; grade 2, 
P = 0.0001; grade 3, P = 0.0029; grade 4, P = 0.02). In contrast, 
in BT- and BTFD-dosed mice most fields of view (94.9% for 
both treatments) scored 0–1. This was comparable to control 
mice, in which 98.5% of fields of view had no pathology, and 
the remainder scored grade 1. When comparing DSS/BT and 
DSS/BTFD mice with the DSS group, a significant improve-
ment was observed in all grades of histopathology scores apart 
from grade 1 (grade 0, P = 0.0001 for BT and P = 0.0001 for 
BTFD; grade 2, P = 0.0025 and P = 0.0007; grade 3, P = 0.0029 
and P = 0.0081; grade 4, P = 0.0215 and P = 0.0479).
B. thetaiotaomicron Is Partially Protective 
Against DSS in Hooded Lister Rats
Adult rats are commonly used in studies of DSS colitis.27 
The aim of this experiment was to assess if  prophylactic treat-
ment with BT could limit the severity of acute colitis in a differ-
ent animal model. Hooded Lister rats were dosed with BT for 
7 days. A group of control rats was dosed with culture medium 
daily. The BT-dosed rats and controls were then also given DSS 
for 7 days (4% DSS for 5 days and 2% DSS for 2 days).
While weight gain was reduced by dosing with DSS, daily 
administration of BT had no significant effect on preventing 
this weight loss (Fig. 4A and B). However, while colon length 
was significantly reduced (P < 0.001) in rats administered DSS 
alone (Fig. 4C), this reduction was not evident when animals 
were treated with BT. Indeed, colon lengths in these rats were 
not significantly different to control animals.
Dextran sodium sulphate caused mild histopathological 
disruption in the ascending colon of rats, with 34% of fields of 
view having major (grade 2 or 3) pathology, 40% with grade 1 
pathology, and 26% with no pathology (Fig. 4D). Bacteroides 
thetaiotaomicron significantly reduced the severity of this DSS-
colitis. Rats administered BT had reduced cellular infiltration, 
over 50% of fields of view had no pathology (P < 0.05 versus 
DSS alone), and only 13% had grade 2 or 3 pathology (P < 0.05 
DSS/BT versus DSS).
A Pirin-Like Protein of B. thetaiotaomicron Is 
Protective in Rats With DSS-Colitis
To identify potential bacterial protein(s) involved in the 
anti-inflammatory effect of BT in colitis, BT was incubated 
with Caco-2 human intestinal epithelial cells for 2 hours, and 
bacterial gene expression was assessed on a Bacteroides thetaio-
taomicron VPI-5482 specific microarray. Forty-three BT genes 
were upregulated by 5-fold or more, and of these, 20 genes 
encoded hypothetical proteins (Table S1). These included the 
pirin-like protein BT_0187 (gene ID 1075517; gene symbol 
BT_0187; accession no. NC_004663.1). A  second hypothet-
ical pirin-related protein, BT_1576, was also elevated, albeit 
to a lesser extent, after exposure of BT to epithelial cells. As 
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mammalian pirin is an iron-binding nuclear protein and an 
important cotranscription factor that promotes activation of 
NF-κB-dependent genes28 and BT was previously shown to 
affect NF-κB signalling,21 we postulated that pirin-like protein 
BT_0187 (PLP) could influence this inflammatory pathway 
in host cells. Pirin-like protein BT_0187 was transfected into 
FIGURE 3. Lyophilized B. thetaiotaomicron maintains its protective activity in murine DSS-colitis. A, Weight change of DSS-treated mice dosed with 
B. thetaiotaomicron (approximately 1 × 1010 CFU /kg BW) or culture media for 8 days. Both BT and BTFD treatment reduced weight loss caused by 
DSS, and (B) this effect was maintained until time of termination. C, DSS treatment significantly reduced colon length; this was partially ameliorated 
in the BT treated group and in the BTFD group. D, DSS-induced histopathology was reduced in mice dosed with BT and BTFD. Top panel shows rep-
resentative scans of H&E stained complete transverse cross sections of ascending colons. The images below show areas selected from the scans and 
digitally zoomed, illustrating the degree of pathology observed between groups. E, Histopathology scores show that mice treated with DSS exhib-
ited a high degree of pathology which was significantly reduced with BT and BTFD treatment
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Caco-2 cells to investigate if  it could affect NF-κB-dependent 
pro-inflammatory responses. Interestingly, epithelial cells trans-
fected with PLP had lower basal levels of NF-κB-responsive 
luciferase activity (Fig. 5A). Furthermore, PLP greatly reduced 
the NF-κB-dependent responsiveness of the cells to flagellin, 
phorbol-12–myristate-13 acetate (PMA), and IL-1 (Fig. 5A).
Recombinant PLP (6His-Tev-Yhhw) was produced 
in Lactococcus lactis and encapsulated into size 9 capsules. 
Its ability to modulate DSS-induced colitis was evaluated in 
Hooded Lister rats given DSS in water for 7 days (as described 
previously). The rats were orally dosed daily with capsules of 
PLP (12 nmole/rat/d) or placebo during this same time period.
Rats given DSS alone lost weight over the experimental 
period (Fig. 5B and C). In contrast, animals treated with PLP 
gained weight slowly, similar to control rats. Colon length was 
significantly reduced due to intake of  DSS (P < 0.05 compared 
with control and P  <  0.01 compared with PLP; Fig.  5D). 
However, this reduction in colon length was prevented when 
rats were treated with PLP. Dextran sodium sulphate caused 
moderate disruption of  the colonic mucosa of  Hooded Lister 
rats (Fig.  4 and 5). As in other models of  colitis, there was 
interanimal and local-site variation in the nature, extent, and 
severity of  the disruption caused in the colon. Histopathology 
scores after PLP treatment were not statistically different from 
DSS-treated mice, although the increase in the percentage of 
fields showing 0 scores showed the same trend as in the pre-
vious study (Fig. 5E). Thus, PLP was able to partially reca-
pitulate the protective effect of  whole BT in a DSS model of 
colitis.
DISCUSSION
The genus Bacteroides is recognized as a dominant and 
biologically important group of commensal bacteria in the 
microbiota of the human gastrointestinal tract.16 Bacteroides 
spp. have been attributed with symbiotic traits related to immu-
noregulatory, metabolic and homeostatic functions. As one 
of the most dominant Bacteroides species within the human 
gut,29, 30 B. thetaiotaomicron has been the subject of a number 
of studies regarding its beneficial effects on the host.19, 20, 31–33 
Importantly in the context of CD, B.  thetaiotaomicron main-
tains immune homeostasis in the gut.20, 21, 34, 35 In germ-free mice, 
this species can recapitulate the effects of the entire conven-
tional microbiota on immune system maturation, in particular 
related to regulatory T cell pathways.35 Bacteroides thetaio-
taomicron also exerts immunomodulating actions on the host 
through altering the activity of the transcription factor NF-κB 
and preventing the downstream induction of inflammatory fac-
tors such as IL-8, TNF-α, and IL-1β.21 These functional effects 
on the host are particularly relevant for IBD because disease 
FIGURE 4. B. thetaiotaomicron is partially protective against DSS-colitis in Hooded Lister rats. A, Weight gain was significantly reduced in animals 
given DSS. This loss of condition was not prevented in rats pretreated with BT compared with DSS alone. B, Total body weight change of DSS/
BT-treated rats was not significantly different from DSS-treated rats; however, (C) the reduction in colon length was statistically improved with BT 
treatment, and (D) there was a statistical improvement in the percentage of fields of view with no pathology when compared with DSS.
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is associated with increased inflammatory cytokine levels and 
NF-κB levels in the intestinal lamina propria.36
Here, we demonstrate that B. thetaiotaomicron has protec-
tive effects on the primary efficacy readouts of colitis including 
weight loss, colon length, histopathological scoring and inflam-
matory mediators. The striking effects of B.  thetaiotaomicron 
treatment on mucosal histopathology are of specific interest 
as therapeutic strategies in the IBD clinical field are moving 
towards a treat-to-target approach, with endoscopic mucosal 
healing the most predictive factor for sustained remission.2, 37
Bacteroides thetaiotaomicron showed efficacy in 2 dif-
ferent preclinical IBD models with relevance for CD: the DSS 
model and the IL10KO model. Although no single animal 
model of IBD can fully recapitulate the complexity of human 
disease, the selected models display characteristics similar to 
that of human CD.24, 38 The DSS colitis model is considered 
a suitable model for investigating pathogenesis, therapeutic 
options and the dysplasia-adenocarcinoma sequence of IBD.39 
Colon damage in this model has similar pathophysiological fea-
tures to human disease, with extensive ulceration of the epithe-
lial layer, fibrotic thickening of the mucosa, loss of crypts and a 
dense cellular infiltrate that includes neutrophils and inflamma-
tory macrophages.24, 40 The C57BL/6 mouse strain in particular 
shows high susceptibility to DSS-induced colitis compared with 
other strains.41 Treatment with B. thetaiotaomicron had striking 
ameliorating effects on disease pathology in these animals. The 
response to B. thetaiotaomicron treatment in DSS-treated rats 
was not as significant as the results obtained in mice, with sig-
nificant amelioration of colon shortening and histopathological 
damage but no reduction in weight loss. This lack of effect on 
body weight may be attributed to the less severe colitis induced 
in this species, and the response to BT might have been more 
pronounced with a higher DSS concentration. Additionally, 
disease course, severity and location of pathological changes 
of DSS-induced intestinal inflammation vary between animal 
species and strains.42, 43 This variability is likely due to a combi-
nation of different factors including genetic background, hus-
bandry conditions and the gut microbiome composition. How 
these factors affect the species- and strain-specific response to 
DSS administration warrants further investigation.
The IL10KO B6.129P2-Il10tm1Cgn/J mutant mouse strain 
spontaneously develops a chronic form of enterocolitis asso-
ciated with altered lymphocyte and myeloid profiles, altered 
responses to inflammatory or autoimmune stimuli and 
increased prevalence of colorectal adenocarcinoma. Similar to 
the human disease, the IL10KO model of CD is responsive to 
anti-TNF therapy and thus is a relevant model for evaluating 
novel therapeutic approaches.38 As B.  thetaiotaomicron effec-
tively ameliorated colitis in IL10KO mice, it may be a targeted 
therapy for patient populations associated with loss of function 
FIGURE 5. A hypothetical protein produced by B. thetaiotaomicron is protective in rats with DSS-colitis. A, Luciferase ratios obtained for Caco-2 cells 
transfected with pTarget-PLP and incubated with flagellin of Salmonella enteritidis, phorbol-12–myristate-13 acetate (PMA) or IL-1 show a reduction 
in NF-κB-dependent responsiveness by PLP treatment. B, Body weight change across the duration of the trial showed that DSS-treated animals had 
the greatest growth reduction, whereas PLP treatment improved weight gain to almost similar levels as control animals. C, The total body weight 
change at termination of study was statistically improved in the PLP group over DSS alone. D, Colon length was significantly reduced due to intake 
of DSS, but this reduction in colon length was prevented when rats were also treated with PLP. E, Histopathology scores were not statistically differ-
ent from DSS-treated mice, although the increase in the percentage of fields showing 0 scores showed the same trend as in the previous study.
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mutations in IL-10 or the IL-10 receptor, such as infant-onset 
(under 2 years old) and very-early-onset (2–6 years old) IBD.44 
Disorders in these populations are particularly complex—even 
in first presentation at clinic—and are poorly responsive to 
standard therapies.45, 46
Overall, B.  thetaiotaomicron treatment reduced the 3 
main histopathology categories assessed in the current stud-
ies, namely crypt hyperplasia, epithelial integrity and infiltrat-
ing inflammatory cells.47 Although not scored as an individual 
pathology, colonic goblet cell mucin depletion also appeared 
to be reduced in B.  thetaiotaomicron–treated animals. These 
findings correlate well with histopathological findings in 
human IBD, which include inflammatory cell infiltration of 
eosinophils, neutrophils, monocytes and mast cells into the gut 
mucosa, goblet cell depletion, crypt abscesses and distortion of 
mucosal glands.48 Prevention of goblet cell depletion by B. the-
taiotaomicron is of specific interest as an article by Wrzosek 
et al20 has previously shown that B. thetaiotaomicron enhances 
goblet cell differentiation in the colon of gnotobiotic rat and 
affects the specific composition of mucin O-glycans.
Animals treated with B. thetaiotaomicron showed strong 
downregulation of proinflammatory genes including Arg1, Il6, 
Ccl3, Spp1, Il1a, and genes involved in pathogen recognition, 
such as Clec4e and Irg1. In particular, Arg1 was identified as 
a potential biomarker of treatment response. Arginase I is an 
endogenous antagonist to nitric oxide (NO) synthase.40 Nitric 
oxide regulates many processes including blood flow, vascular 
permeability, mucosal defence and immune regulation. Nitric 
oxide production is decreased in chronically inflamed gut 
blood vessels in CD and UC, whereas arginase is upregulated.49 
Reconstitution of NO metabolism by inhibition of arginase 
activity has potential therapeutic effects in IBD.40 Increased 
expression of the transcripts for Il6, Ccl3, Spp1, Il1a, Clec4e 
and Irg1 was also observed. All of these genes are increased 
in human IBD and play roles in the inflammatory cascade 
through their effects on different innate immune populations 
including macrophages and dendritic cells.50 For instance, Spp1 
is the murine ortholog of Osteopontin (OPN), a Th1 inflam-
matory mediator which is increased in the lamina propria of 
CD and UC patients and is directly related to the severity of 
inflammation.51, 52
Protective effects of some other Bacteroides species in 
animal models of colitis have been demonstrated in previous 
studies. Bacteroides vulgatus53 and Bacteroides ovatus54 have 
shown beneficial effects in DSS models. Bacteroides fragilis 
has shown efficacy in different experimental colitis models,55, 56  
and a protective role has been identified for polysaccharide 
A55 and outer membrane vesicles57 produced by this bacterial 
species. We present preliminary evidence of a pirin-like protein 
that ameliorated DSS-colitis when given orally to rats. While 
more work is needed to understand the exact mechanisms by 
which this protein conveys protection, our working hypoth-
esis is that it modulates nuclear shuttling of NF-κB Rel A in 
stimulated cells in a manner similar to the whole bacterium. 
Further investigations should also show whether this pirin-like 
protein is solely responsible for the beneficial effects of B. the-
taiotaomicron or whether additional signalling molecules or 
mechanisms are involved.
CONCLUSION
This study shows that treatment with B.  thetaiotaomi-
cron has protective effects in DSS and IL10KO models of  coli-
tis in both mice and rats. The strain we used was able to protect 
against weight loss, histopathological changes of  the colon 
and inflammatory parameters. This efficacy was not exclusive 
to actively growing bacterial preparations but was maintained 
in a freeze-dried formulation. These encouraging data also 
indicate that a pirin-like protein produced by B. thetaiotaomi-
cron was able to at least partially recapitulate the effect of  the 
whole strain. Further work is needed to precisely understand 
the specific mechanisms by which B. thetaiotaomicron and its 
products interact with the host to exert its therapeutic effects.
SUPPLEMENTARY DATA
Supplementary data is available at Inflammatory Bowel 
Diseases online.
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